Samarpit Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-12-2024
- Paid Up Capital ₹ 0.20 M
as on 21-12-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2017)
- Profit -1098.44%
(FY 2017)
- Ebitda -1110.51%
(FY 2017)
- Net Worth -37.83%
(FY 2017)
- Total Assets -37.83%
(FY 2017)
About Samarpit Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Jagat Bishwas and Vaibhav Sinha serve as directors at the Company.
- CIN/LLPIN
U74120UP2014PTC066636
- Company No.
066636
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Jaunpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Samarpit Pharmaceuticals Private Limited offer?
Samarpit Pharmaceuticals Private Limited offers a wide range of products and services, including Measuring Equipments & Instruments, Measurement Instrument.
Who are the key members and board of directors at Samarpit Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaibhav Sinha  | Director | 20-Oct-2014 | Current |
| Jagat Bishwas | Director | 20-Oct-2014 | Current |
Financial Performance of Samarpit Pharmaceuticals.
Samarpit Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1098.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 37.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Samarpit Pharmaceuticals?
In 2017, Samarpit Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sondhi Krishak Sabzi Producer Company LimitedActive 3 years 5 monthsJagat Bishwas is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Samarpit Pharmaceuticals?
Unlock and access historical data on people associated with Samarpit Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Samarpit Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Samarpit Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
